Top-News

Zymeworks Aktie News

Aktie
WKN:  A3DSSN ISIN:  US98985Y1082 US-Symbol:  ZYME Branche:  Biotechnologie Land:  USA
26,69 $
+0,17 $
+0,64%
22,922 € 05.12.25
Depot/Watchlist
Marktkapitalisierung *
1,10 Mrd. €
Streubesitz
-
KGV
-9,04
Index-Zuordnung
-

Zymeworks News

18.11.25 - GlobeNewswire
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare ...
18.11.25 - GlobeNewswire
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
Strategy will combine internal innovation, licensing, and strategic acquisitions to drive sustainable value creation for shareholders Strategic initiative follows positive topline results ...
17.11.25 - GlobeNewswire
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
Ziihera® plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful ...
23.10.25 - GlobeNewswire
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-...
15.10.25 - PR Newswire
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
Next-​Generation Targeted Therapies Reshape Precision Oncology Landscape PR Newswire
15.10.25 - PR Newswire
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
Next-​Generation Targeted Therapies Reshape Precision Oncology Landscape PR Newswire
13.10.25 - GlobeNewswire
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
Preliminary data presented at the AACR-​NCI-EORTC conference will provide insights into the potential of ZW191 in patients with advanced solid tumors, including ovarian cancer, ...
09.10.25 - GlobeNewswire
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-​stage biotechnology company developing a diverse pipeline of ...
02.09.25 - GlobeNewswire
Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager
VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-​stage biotechnology company developing a diverse pipeline of ...
19.08.25 - GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-​stage biotechnology company developing a diverse pipeline of ...
11.08.25 - GlobeNewswire
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
VANCOUVER, British Columbia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-​stage biotechnology company developing a diverse pipeline of ...
28.07.25 - GlobeNewswire
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
Second antibody-​drug conjugate (ADC) to progress into clinical development utilizing our proprietary payload and optimized antibody Preclinical results demonstrate strong anti-...
17.07.25 - GlobeNewswire
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
Company to participate in investor conferences in July and August
30.05.25 - GlobeNewswire
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval based on the results of the HERIZON-...
22.05.25 - GlobeNewswire
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
Partner presentations reinforce ability of proprietary Azymetric™ platform to develop clinically validated therapeutic antibodies Long-term outcomes and survival data for Ziihera® ...
21.05.25 - GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, May 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-​stage biotechnology company developing a diverse pipeline of ...
19.05.25 - GlobeNewswire
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference
Company’s first development candidate in autoimmune and inflammatory disease (AIID) demonstrates potent blockade of IL-4, IL-13, and IL-33 signaling pathways critical in ...
25.04.25 - GlobeNewswire
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
Six posters highlight continued progress across antibody-​drug conjugate and T cell engager platforms
21.04.25 - GlobeNewswire
Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development
VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-​stage biotechnology company developing a diverse pipeline of ...
26.03.25 - GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-​stage biotechnology company developing a diverse pipeline of ...

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »